Mind the gap: Jumping from vaccine licensure to routine use

The Lancet

Volumn 387, Issue 10031, 2016, Pages 1887-1889

  O'Brien, Katherine L ^a   Binka, Fred ^b   Marsh, Kevin ^c   Abramson, Jon S ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Ghana)

^c AFRICAN ACADEMY OF SCIENCES   (Kenya)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; EBOLA VACCINE; MALARIA VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; STREPTOCOCCUS VACCINE; VACCINE;

CHILD HEALTH; DENGUE; EBOLA HEMORRHAGIC FEVER; GROUP B STREPTOCOCCAL MENINGITIS; HUMAN; IMMUNIZATION; INFECTION; MALARIA; NONHUMAN; NOTE; POLICY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SURVIVAL RATE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; HEALTH; LICENSING; MASS COMMUNICATION; SUPPLY AND DISTRIBUTION;

CLINICAL TRIALS AS TOPIC; DIFFUSION OF INNOVATION; DRUG APPROVAL; GLOBAL HEALTH; HUMANS; LICENSURE; VACCINES;

EID: 84966349663     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30394-4     Document Type: Note

References (12)

1. RTS,S Clinical Trials Partnership Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial Lancet 386 2015 31 45
2. H Christensen, M Hickman, WJ Edmunds, CL Trotter Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact Vaccine 31 2013 2638 2646
3. European Medicines Agency Summary of opinion: Mosquirix Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) http://www.ema.europa.eu/docs/en-GB/document-library/Other/2015/07/WC500190452.pdf July 23, 2015 (accessed April 26, 2016).
4. RTS,S Clinical Trials Partnership A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants N Engl J Med 367 2012 2284 2295
5. RTS,S Clinical Trials Partnership Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites PLoS Med 11 2014 e1001685
6. ST Agnandji, B Lell, SS Soulanoudjingar et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children N Engl J Med 365 2011 1863 1875
7. WHO Malaria vaccine: WHO position paper. January 2016 Wkly Epidemiol Rec 91 2016 33 51
8. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2015 - conclusions and recommendations Wkly Epidemiol Rec 90 2015 681 699
9. MA Penny, R Verity, CA Bever et al. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models Lancet 387 2016 367 375
10. WHO Global technical strategy for malaria 2016-2030 2015 World Health Organization Geneva
11. WHO World malaria report 2015 2015 World Health Organization Geneva
12. C Lengeler Insecticide-treated bed nets and curtains for preventing malaria Cochrane Database Syst Rev 2 2004 CD000363.